U.S. Urology Partners

U.S. Urology Partners

U.S. Urology Partners operates as a holding entity for urology practices, founded to professionalize and aggregate a physician specialty long resistant to large-scale consolidation. The platform is led by Executive Chairman Mark L. Baum, who also serves as managing partner of the healthcare-focused private equity firm, Altos Partners. The business model centers on acquiring majority stakes in established urology groups while retaining physician partners as minority equity holders — a structure designed to align clinical autonomy with operational scale. The firm is headquartered in Gahanna, Ohio, a suburb of Columbus, placing it near a rich concentration of independent Midwestern medical practices that form the core of its initial acquisition strategy. U.S. Urology Partners focuses exclusively on urology, covering general urology, urologic oncology, men's health, female pelvic medicine, and advanced surgical interventions including robotic surgery. The investment thesis targets the full ancillary service chain — in-office procedures, pathology labs, radiation oncology, and diagnostic imaging — converting revenue traditionally lost to hospital referrals into in-network, practice-owned profit centers. Its deal structure typically pairs a platform practice with subsequent add-on acquisitions in contiguous geographies. Confirmed operating regions include Ohio and Indiana, with demonstrated expansion into Florida. The firm competes against other private-equity-backed urology roll-ups, including Solaris Health and United Urology Group, in a wave of consolidation reshaping the specialty. The platform's scale flows from a buy-and-build strategy that has remained tightly focused on urology rather than diversifying across medical specialties. The management team combines Baum's private equity sourcing with an in-house clinical leadership group of urologists who vet potential practice partners. While total deployment and AUM remain undisclosed, the firm has closed multiple platform acquisitions and has disclosed plans to expand into additional states in the Midwest and Southeast. U.S. Urology Partners has not announced dedicated philanthropic vehicles or real-asset arms, operating purely as a healthcare services investment platform. No team-size figures or recent fund-closing dates were publicly available; the firm does not publish regular operating metrics. U.S. Urology Partners' structural differentiation lies in its pure-play urology mandate within a consolidating physician practice management sector. Most scaled practice management platforms target primary care, dermatology, or gastroenterology; urology remains less mature, offering early movers a wider field for acquisitions and potentially lower multiples. The firm's governance embeds physician co-ownership, placing practicing urologists on local boards and within clinical committees — a structure designed to insulate medical decisions from investor pressure. Succession risk, however, concentrates around Baum, who has not publicly designated a successor. The model's durability will be tested as the remaining high-quality independent groups dwindle and competition for targets intensifies.